Neo-adjuvant immunotherapy combination effective for non-metastatic bladder cancer


This week, researchers at the Netherlands Cancer Institute published the results of the NABUCCO study in scientific journal Nature Medicine. In this publication, they show that neoadjuvant immunotherapy using a combination of two drugs (nivolumab and ipilimumab) is a feasible treatment for bladder cancer without harming the scheduled resection, and shows promising results.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.